目的 分析上海市青浦区赵巷镇2019—2023年疑似预防接种异常反应（adverse event following immunization，AEFI）分布状况，为评价疫苗接种的安全性和提升预防接种服务质量提供依据。方法 分别通过中国疾病预防控制信息系统和上海市疫苗综合管理和预防接种服务信息系统收集2019—2023年上海市青浦区赵巷镇AEFI和疫苗接种数据，并采用描述性流行病学方法进行分析。结果 2019—2023年上海市青浦区赵巷镇共报告AEFI 504例，年平均报告发生率为355.18/10万剂。一般反应（99.01%）以发热（45.24%）和局部反应（42.86%）为主，异常反应（0.99%）均为过敏性皮疹。男性略多于女性（1.20∶1.00），<1岁儿童占比最高（53.77%）。83.73%的AEFI发生在接种后1 d内。带状疱疹疫苗报告发生率最高，白喉-破伤风-无细胞百日咳疫苗其次，白喉-破伤风-无细胞百日咳-流感嗜血杆菌b结合疫苗（四联疫苗）以及13价肺炎球菌疫苗（结合）的报告发生率也较高。结论 赵巷镇AEFI以一般反应为主，异常反应发生率较低，表明疫苗接种安全性良好；建议重点加强1岁以内儿童和接种后24 h内的AEFI监测。

Objective To analyze the distribution of adverse events following immunization (AEFIs) in Zhaoxiang Town, Qingpu District, Shanghai from 2019 to 2023, and provide a basis for evaluating the safety of vaccination and improving the quality of vaccination services.Methods AEFI and vaccination data in Zhaoxiang Town, Qingpu District, Shanghai from 2019 to 2023 were collected through China Disease Control and Prevention Information System and Shanghai Integrated Vaccine Management and Vaccination Service Information System, respectively, and analyzed using descriptive epidemiological methods.Results From 2019 to 2023, a total of 504 AEFI cases were reported in Zhaoxiang Town, Qingpu District, Shanghai, with an average annual reported incidence of 355.18/100 000 doses. General reactions (99.01%) were mainly fever (45.24%) and local reactions (42.86%). Abnormal reactions (0.99%) were all allergic rash. There were slightly more males than females (1.20∶1.00), and children < 1 year old accounted for the highest proportion (53.77%). Among all AEFIs，83.73% occurred within 1 d after vaccination. Herpes zoster vaccine accounted for the highest reported incidence, followed by diphtheria, tetanus and acellular pertussis combined vaccine (DTaP), and DTaP-Haemophilus influenzae type b conjugate vaccine (quadruple vaccine) and 13-valent pneumococcal vaccine (conjugate) were also reported at a higher incidence.Conclusions AEFI in Zhaoxiang Town is dominated by general reactions, with a low incidence of abnormal reactions， which shows good safety of vaccination.It is recommended to focus on strengthening AEFI monitoring in children under 1 year old and within 24 h after vaccination.